{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:43:54Z","timestamp":1762004634075},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T00:00:00Z","timestamp":1404432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00441-014-1922-9","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T08:20:15Z","timestamp":1404375615000},"page":"217-227","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease."],"prefix":"10.1007","volume":"358","author":[{"given":"Stefan","family":"Porubsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Jennemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann-Josef","family":"Gr\u00f6ne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,4]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","volume":"105","author":"A Abe","year":"2000","unstructured":"Abe A, Gregory S, Lee L, Killen PD, Brady RO, Kulkarni A, Shayman JA (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105:1563\u20131571","journal-title":"J Clin Invest"},{"key":"1922_CR2","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812\u20132817","journal-title":"Proc Natl Acad Sci USA"},{"key":"1922_CR3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"W Anderson","year":"1898","unstructured":"Anderson W (1898) A case of \u201cangeio-keratoma\u201d. Br J Dermatol 10:113\u2013117","journal-title":"Br J Dermatol"},{"key":"1922_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","volume":"93","author":"C Auray-Blais","year":"2008","unstructured":"Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melan\u00e7on SB, Stockley T, Clarke JTR, Drouin R (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 93:331\u2013340","journal-title":"Mol Genet Metab"},{"key":"1922_CR5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1194\/jlr.M010819","volume":"52","author":"J Betz","year":"2011","unstructured":"Betz J, Bielaszewska M, Thies A, Humpf HU, Dreisewerd K, Karch H, Kim KS, Friedrich AW, Muthing J (2011) Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: differential association with membrane lipid raft microdomains. J Lipid Res 52:618\u2013634","journal-title":"J Lipid Res"},{"key":"1922_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","volume":"57","author":"RO Brady","year":"2006","unstructured":"Brady RO (2006) Enzyme Replacement for Lysosomal Diseases. Annu Rev Med 57:283\u2013296","journal-title":"Annu Rev Med"},{"key":"1922_CR7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic Defect in Fabry\u2019s Disease. N Engl J Med 276:1163\u20131167","journal-title":"N Engl J Med"},{"key":"1922_CR8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1423-0127-17-26","volume":"17","author":"J Choi","year":"2010","unstructured":"Choi J, Lee MH, Park H, Jung S (2010) Characterization of Fabry mice treated with recombinant adeno-associated virus 2\/8-mediated gene transfer. J Biomed Sci 17:26","journal-title":"J Biomed Sci"},{"key":"1922_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","volume":"146","author":"JTR Clarke","year":"2007","unstructured":"Clarke JTR (2007) Narrative review: Fabry disease. Ann Intern Med 146:425\u2013433","journal-title":"Ann Intern Med"},{"key":"1922_CR10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","volume":"35","author":"P Deegan","year":"2012","unstructured":"Deegan P (2012) Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 35:227\u2013243","journal-title":"J Inherit Metab Dis"},{"key":"1922_CR11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. Ann Intern Med 138:338\u2013346","journal-title":"Ann Intern Med"},{"key":"1922_CR12","first-page":"CD006663","volume":"2","author":"RP Dib El","year":"2013","unstructured":"El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663","journal-title":"Cochrane Database Syst Rev"},{"key":"1922_CR13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"J Fabry","year":"1898","unstructured":"Fabry J (1898) Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) [A contribution to knowledge on the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Arch Dermatol Syph 43:187\u2013200","journal-title":"Arch Dermatol Syph"},{"key":"1922_CR14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"CEM Hollak","year":"2009","unstructured":"Hollak CEM, Hughes D, van Schaik IN, Schwierin B, Bembi B (2009) Miglustat (Zavesca\u00ae) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 18:770\u2013777","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1922_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0022-2275(20)43219-5","volume":"31","author":"I Hozumi","year":"1990","unstructured":"Hozumi I, Nishizawa M, Ariga T, Miyatake T (1990) Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry\u2019s disease) in comparison with hemizygotes. J Lipid Res 31:335\u2013340","journal-title":"J Lipid Res"},{"key":"1922_CR16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936\u2009+\u2009919G\u2009>\u2009A (IVS4\u2009+\u2009919G\u2009>\u2009A). Hum Mutat 30:1397\u20131405","journal-title":"Hum Mutat"},{"key":"1922_CR17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.plipres.2013.02.001","volume":"52","author":"R Jennemann","year":"2013","unstructured":"Jennemann R, Gr\u00f6ne H-J (2013) Cell-specific in vivo functions of glycosphingolipids: Lessons from genetic deletions of enzymes involved in glycosphingolipid synthesis. Prog Lipid Res 52:231\u2013248","journal-title":"Prog Lipid Res"},{"key":"1922_CR18","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1073\/pnas.051634498","volume":"98","author":"S-C Jung","year":"2001","unstructured":"Jung S-C, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P (2001) Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 98:2676\u20132681","journal-title":"Proc Natl Acad Sci USA"},{"key":"1922_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/03009734.2011.641609","volume":"117","author":"M Machaczka","year":"2012","unstructured":"Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, H\u00e4gglund H (2012) Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci 117:28\u201334","journal-title":"Ups J Med Sci"},{"key":"1922_CR20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/HYPERTENSIONAHA.109.141127","volume":"55","author":"P Malekar","year":"2010","unstructured":"Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, Wolf D, Riffel J, Bauer A, Katus HA, Hardt SE (2010) Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 55:939\u2013945","journal-title":"Hypertension"},{"key":"1922_CR21","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","volume":"5","author":"J Marshall","year":"2010","unstructured":"Marshall J, Ashe KM, Bangari D, McEachern K, Chuang W-L, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, Cheng SH (2010) Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease. PLoS ONE 5:e15033","journal-title":"PLoS ONE"},{"key":"1922_CR22","doi-asserted-by":"crossref","first-page":"e33743","DOI":"10.1371\/journal.pone.0033743","volume":"7","author":"A Nguyen Dinh Cat","year":"2012","unstructured":"Nguyen Dinh Cat A, Escoubet B, Agrapart V, Griol-Charhbili V, Schoeb T, Feng W, Jaimes E, Warnock DG, Jaisser F (2012) Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease. PLoS ONE 7:e33743","journal-title":"PLoS ONE"},{"key":"1922_CR23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.heares.2007.08.009","volume":"234","author":"K Noben-Trauth","year":"2007","unstructured":"Noben-Trauth K, Neely H, Brady RO (2007) Normal hearing in \u03b1-galactosidase A-deficient mice, the mouse model for Fabry disease. Hear Res 234:10\u201314","journal-title":"Hear Res"},{"key":"1922_CR24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","volume":"94","author":"T Ohashi","year":"2008","unstructured":"Ohashi T, Iizuka S, Ida H, Eto Y (2008) Reduced \u03b1-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 94:313\u2013318","journal-title":"Mol Genet Metab"},{"key":"1922_CR25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T Ohshima","year":"1997","unstructured":"Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94:2540\u20132544","journal-title":"Proc Natl Acad Sci USA"},{"key":"1922_CR26","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","volume":"96","author":"T Ohshima","year":"1999","unstructured":"Ohshima T, Schiffmann R, Murray GJ, Kopp J, Quirk JM, Stahl S, Chan CC, Zerfas P, Tao-Cheng JH, Ward JM, Brady RO, Kulkarni AB (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 96:6423\u20136427","journal-title":"Proc Natl Acad Sci USA"},{"key":"1922_CR27","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1074\/jbc.M600057200","volume":"281","author":"T Okuda","year":"2006","unstructured":"Okuda T, Tokuda N, Numata S, Ito M, Ohta M, Kawamura K, Wiels J, Urano T, Tajima O, Furukawa KK (2006) Targeted disruption of Gb3\/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 281:10230\u201310235","journal-title":"J Biol Chem"},{"key":"1922_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","volume":"107","author":"A Pisani","year":"2012","unstructured":"Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, Imbriaco M (2012) Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature. Mol Genet Metab 107:267\u2013275","journal-title":"Mol Genet Metab"},{"key":"1922_CR29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1098\/rstb.2003.1279","volume":"358","author":"FM Platt","year":"2003","unstructured":"Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek R a, Butters TD (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B 358:947\u2013954","journal-title":"Philos Trans R Soc Lond B"},{"key":"1922_CR30","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1073\/pnas.0611139104","volume":"104","author":"S Porubsky","year":"2007","unstructured":"Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Gr\u00f6ne H-J (2007) Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 104:5977\u20135982","journal-title":"Proc Natl Acad Sci USA"},{"key":"1922_CR31","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.4049\/jimmunol.1201483","volume":"189","author":"S Porubsky","year":"2012","unstructured":"Porubsky S, Speak AO, Salio M, Jennemann R, Bonrouhi M, Zafarulla R, Singh Y, Dyson J, Luckow B, Lehuen A, Malle E, Muthing J, Platt FM, Cerundolo V, Grone HJ (2012) Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells. J Immunol 189:3007\u20133017","journal-title":"J Immunol"},{"key":"1922_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jgm.468","volume":"6","author":"M Przybylska","year":"2004","unstructured":"Przybylska M, Wu I-H, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS (2004) Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. J Gene Med 6:85\u201392","journal-title":"J Gene Med"},{"key":"1922_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2008.09.001","volume":"33","author":"LG Rodrigues","year":"2009","unstructured":"Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, S\u00e1-Miranda MC (2009) Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol Dis 33:48\u201356","journal-title":"Neurobiol Dis"},{"key":"1922_CR34","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg F a, Hollak CEM, Linthorst GE (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE 7:e47805","journal-title":"PLoS ONE"},{"key":"1922_CR35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"S Rombach","year":"2013","unstructured":"Rombach S, Smid B, Bouwman M, Linthorst G, Dijkgraaf MGW, Hollak CEM (2013a) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47","journal-title":"Orphanet J Rare Dis"},{"key":"1922_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Hollak CEM, Linthorst GE, Dijkgraaf MGW (2013b) Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis 8:29","journal-title":"Orphanet J Rare Dis"},{"key":"1922_CR37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cjca.2010.12.035","volume":"27","author":"PA Rozenfeld","year":"2011","unstructured":"Rozenfeld PA, Fritz M, Blanco P, Gonzalez P, Rinaldi GJ (2011) Myocardial Alterations in the Murine Model of Fabry Disease Can Be Reversed by Enzyme Replacement Therapy. Can J Cardiol 27:339\u2013345","journal-title":"Can J Cardiol"},{"key":"1922_CR38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65\u201367","journal-title":"Pharmacol Ther"},{"key":"1922_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","volume":"19","author":"MN Sheppard","year":"2010","unstructured":"Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J, Lee P, Elliott P (2010) A detailed pathologic examination of heart tissue from three older patients with Anderson\u2013Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 19:293\u2013301","journal-title":"Cardiovasc Pathol"},{"key":"1922_CR40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"1922_CR41","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1073\/pnas.0607285104","volume":"104","author":"AO Speak","year":"2007","unstructured":"Speak AO, Salio M, Neville DCA, Fontaine J, Priestman DA, Platt N, Heare T, Butters TD, Dwek RA, Trottein F, Exley MA, Cerundolo V, Platt FM (2007) Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci USA 104:5971\u20135976","journal-title":"Proc Natl Acad Sci USA"},{"key":"1922_CR42","doi-asserted-by":"crossref","first-page":"PC3148","DOI":"10.1016\/S0021-9258(18)51888-3","volume":"238","author":"CC Sweeley","year":"1963","unstructured":"Sweeley CC, Klionsky B (1963) Fabry\u2019s Disease: Classification as a Sphingolipidosis and Partial Characterization of a Novel Glycolipid. J Biol Chem 238:PC3148\u2013PC3150","journal-title":"J Biol Chem"},{"key":"1922_CR43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BJ20130825","volume":"456","author":"A Taguchi","year":"2013","unstructured":"Taguchi A, Maruyama H, Nameta M, Yamamoto T, Matsuda J, Kulkarni AB, Yoshioka H, Ishii S (2013) A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem J 456:373\u2013383","journal-title":"Biochem J"},{"key":"1922_CR44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100:257\u2013261","journal-title":"Mol Genet Metab"},{"key":"1922_CR45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137\u2013148","journal-title":"J Am Soc Nephrol"},{"key":"1922_CR46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","volume":"5","author":"AK Topaloglu","year":"1999","unstructured":"Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (1999) Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med 5:806\u2013811","journal-title":"Mol Med"},{"key":"1922_CR47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","volume":"105","author":"WR Wilcox","year":"2012","unstructured":"Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, Beitner-Johnson D, Cizmarik M, Cole JA, Kingma W, Warnock DG (2012) Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry. Mol Genet Metab 105:443\u2013449","journal-title":"Mol Genet Metab"},{"key":"1922_CR48","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1253\/circj.70.1503","volume":"70","author":"M Yoshimitsu","year":"2006","unstructured":"Yoshimitsu M, Higuchi K, Dawood F, Rasaiah VI, Ayach B, Chen M, Liu P, Medin JA (2006) Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ J 70:1503\u20131508","journal-title":"Circ J"},{"key":"1922_CR49","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A (2011) How I treat Gaucher disease. Blood 118:1463\u20131471","journal-title":"Blood"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00441-014-1922-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-014-1922-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-014-1922-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T11:15:46Z","timestamp":1649589346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00441-014-1922-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,4]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1007\/s00441-014-1922-9","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,4]]}}}